Enters Bakar Bio Labs at UC Berkeley

Meridian Innovation (hereinafter, Meridian) announced on October 12 that it recently signed a memorandum of understanding (MOU) with VS Pharmtech to support its entry into the U.S. market and other initiatives.


Meridian is working to build an open platform connecting promising Korean early-stage companies with U.S. universities, research institutions, medical institutions, and venture capital firms. VS Pharmtech will participate as an early leader in this ecosystem and has decided to join Bakar Bio Labs, a leading U.S. incubator for early-stage life sciences companies.


Bakar Bio Labs is a facility on the UC Berkeley campus equipped with advanced research equipment and office space. It helps connect industry experts and investors with pharmaceutical and biotechnology companies. Regardless of their university affiliation, promising early-stage life sciences companies from around the world can use the platform to turn research and development results into investment and commercialization opportunities.


Meridian said it leveraged its local U.S. network to help VS Pharmtech gain entry to the facility. It established connections through its networks at UC Berkeley and in the San Francisco area and supported the company's entry process. Under the MOU, Meridian will support VS Pharmtech's entry into the U.S. market and global business expansion while broadening its network of U.S. investors, pharmaceutical and biotechnology companies, universities, and research and medical institutions. The two companies will also work together to attract overseas investment, identify business models, and pursue technology transfers. VS Pharmtech plans to share the business development experience it gains from entering the U.S. market with other Korean early-stage companies seeking to expand into the country in the future.

Kwon Hoyoon, CEO of Meridian Innovation (left), and Park Shinyoung, CEO of VS Pharmtech, pose for a commemorative photo after signing a business agreement last month. Photo courtesy of Meridian.

Kwon Hoyoon, CEO of Meridian Innovation (left), and Park Shinyoung, CEO of VS Pharmtech, pose for a commemorative photo after signing a business agreement last month. Photo courtesy of Meridian.

View original image

Meridian plans to expand its network beyond any particular university or region. While operating a senior living business in Korea, the company came to recognize the importance of operational services and personalized health management solutions, and began reaching out to domestic early-stage biotechnology and healthcare companies. In the process, it expanded its business to include helping companies increase their prospects for attracting investment and developing business in the United States.



VS Pharmtech is developing an agent that enhances the efficacy of existing cancer treatments. The company is conducting clinical trials in the United States, and has raised a cumulative total of around 18.6 billion won from external investors to date, Meridian said. Park Shinyoung, CEO of VS Pharmtech, said, "Alongside our U.S. clinical trials, we will expand opportunities to attract investment, conduct joint research, and pursue technology transfers." Kwon Hoyoon, CEO of Meridian, said, "We will connect investment and commercialization in the United States with technology transfers, and build an ecosystem where the experience can benefit the next generation of Korean early-stage companies."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing